Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06211335 · ClinicalTrials.gov registry record · Phase 1
Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma
A Phase 1 study of Metastatic Head-and-neck Squamous-cell Carcinoma and Locally Recurrent Head and Neck Squamous Cell Carcinoma, sponsored by University of California, Davis.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT06211335 is a Phase 1 study of Metastatic Head-and-neck Squamous-cell Carcinoma and Locally Recurrent Head and Neck Squamous Cell Carcinoma that is actively recruiting participants, run by University of California, Davis. The registered enrollment target is 24 participants, below the 126-participant average among 24 other Metastatic Head-and-neck Squamous-cell Carcinoma trials with a reported enrollment target (81% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06211335, a Phase 1 study of Metastatic Head-and-neck Squamous-cell Carcinoma and Locally Recurrent Head and Neck Squamous Cell Carcinoma, is actively recruiting participants, sponsored by University of California, Davis.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase Ib trial tests the safety, side effects and how well losartan, pembrolizumab and stereotactic body radiation therapy (SBRT) for the treatment of patients with head and neck squamous cell carcinoma that has come back to nearby tissue or lymph node after a period of improvement (locally recurrent), that has not responded to previous treatment (refractory) or that has spread from where it first started to multiple other placed in the body (oligometastatic). Losartan is a drug used to treat high blood pressure that may enhance the effects of other cancer treatments such as immunotherapy and radiation. Immunotherapy with pembrolizumab may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. SBRT is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. Giving losartan, pembrolizumab and SBRT may work better in treating patients with locally recurrent, refractory or oligometastatic head and neck squamous cell carcinoma.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- RADIATION Stereotactic Body Radiation Therapy
- DRUG Losartan
Study Locations (2)
California
- University of California Davis Comprehensive Cancer Center - Sacramento
Colorado
- University of Colorado Denver | Anschutz Medical Campus - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-12-07 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06211335
The ClinicalTrials.gov registry entry for NCT06211335 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 126-participant average among 24 other Metastatic Head-and-neck Squamous-cell Carcinoma trials with a reported enrollment target (81% lower). The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Metastatic Head-and-neck Squamous-cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT06211335 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Colorado.
Frequently Asked Questions
What is clinical trial NCT06211335 about?
NCT06211335 is a clinical study titled "Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma". This phase Ib trial tests the safety, side effects and how well losartan, pembrolizumab and stereotactic body radiation therapy (SBRT) for the treatment of patients with head and neck squamous cell carcinoma that has come back to nearby tissue or lymph node after a period of improvement (locally rec...
What is the current status of trial NCT06211335?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2023-12-07. Estimated completion is 2027-06.
What conditions does trial NCT06211335 study?
This clinical trial studies the following conditions: Metastatic Head-and-neck Squamous-cell Carcinoma, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Refractory Head and Neck Squamous Cell Carcinoma.
What interventions are being tested in trial NCT06211335?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Stereotactic Body Radiation Therapy (RADIATION), Losartan (DRUG).
Who is sponsoring clinical trial NCT06211335?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06211335 being conducted?
This trial has 2 study locations across California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Head-and-neck Squamous-cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers
RECRUITING · Phase 1
-
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
RECRUITING · Phase 1
-
(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma
RECRUITING · Phase 1
-
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
RECRUITING · Phase 1
-
An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Metastatic Head-and-neck Squamous-cell Carcinoma
All registered trials for this condition
Locally Recurrent Head and Neck Squamous Cell Carcinoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.